Alphyn presents Poster about the clinical experience of Zabalafin-Hydrogel at the European Academy of Dermatology and Venereology Congress 2024

ANNAPOLIS, Maryland., 27. August 2024 /PRNewswire/ – Alphyn Biologics, Inc., a clinical stage dermatology treatment company, the first-in-class Multi-Target Therapeutics^® entwickelt, gab heute kannt, dass aus seiner clinicalen Phase-2a-Humanstudie with Zabalafin-Hydrogel (AB-101a) in atopic dermatitis (AD) at the current European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam from 25 to 28. September 2024 were proposed. Zabalafin Hydrogel is one of the first therapies for AD, which treats the treatment of AD directly and bakes directly, allowing the treatment to last longer, while it is treated and sanded in AD versursachen. Attention has been paid to the direct rolling of AD-Haut and the direct performance of the Entzündung von AD.

The first phase 2a study in humans that conzipiert, one of the most important analyses in AD – Juckreiz and Verbesserung der Lebensqualität – so who will use the Safety and Effectiveness of Zabalafin Hydrogel. Neurodermatitis is a long-term study and the highest form of eczema, the Global Atopic Dermatitis Atlas (GADA) is the largest dermatological problem in the world. The clinical treatment of Zabalafin Hydrogel results that this is the potential hat, the “medicine of the Wahl” with the treatment of AD.

The poster titled “Itch Reduction and Improvement of Quality of Life in AD for the First Human Use of Zabalafin” (Itch Reduction and Improvement of Quality of Life in Alzheimer’s Disease) was published by Lynda SpelmanMD¹, Stephen ShumackMD², Michael BensonMD³Bevin Bhoyrul, MD⁴, Jessie LeeMD⁵Ebrahim AK Abdulla, MD⁶, Neal Koller⁷and Gary Pekoe, PhD⁷ painted.

Zabalafin Hydrogel is a new type of, compound complexes that work a single time with more bioactive compounds, the more mechanisms of action of the action, a small effect on the action, antibacterial action and the action of its action. The active Preparat-stemmt from the Zabalafin-Plattform des Unternehmens.

INFORMATION ON ALPHYN BIOLOGICS

Alphyn Biologics, Inc. is a clinical stage dermatology treatment company, based on the Zabalafin platform’s first-in-class Multi-Target Therapeutics^® for severe and widespread skin diseases. As a product candidate, Zabalafin Hydrogel, is used as a topical treatment for atopic dermatitis (AD), the most severe form of eczema.

Zabalafin Hydrogel in clinical research into phase 2a of the disease, and medicine is of the research, it is the first therapeutic treatment for AD during the period that the disease in the AD-directly detected and directly baked, destroying the man, that sie Entzündungen and Schübe in AD verursachen. Attention has been paid to the direct rolling of AD-Haut and directly performing the Entzündung von AD. The very clinical study with Zabalafin Hydrogel results that this has the potential, the first AD treatment is long-term, the continued improvement can not pose a problem.

Alphyns Zabalafin-Plattform has developed more bioactive active ingredients and more active mechanisms, which offers a robust pipeline of dermatological therapies, which have potential in the use of health, care, patient care, health and nutritional benefits. Alphyn hat signals Sitz Annapolis, Marylandand Cincinnati, Ohioand presents hundreds of proselytizing tours in Australia and Austria. The Unternehmen nahm 2020 den Betrieb auf a hat beef 16 Mio. USD raised.

Logo – https://mma.prnewswire.com/media/1899346/Alphyn_Biologics__LLC__Logo_Hi_Res_Transparent_Bckgrd_Logov1.jpg

View original content: https://www.prnewswire.com/news-releases/alphyn-prasentiert-poster-zu-den-clinicalen-ergebnissen-von-zabalafin-hydrogel-auf-dem-european-academy-of-dermatology- en-venereology-congress-2024-302232060.html